Targeted inhibition of complement activation prevents features of preeclampsia in mice

Kidney International

Volumn 79, Issue 3, 2011, Pages 331-339

  Qing, Xiaoping ^a   Redecha, Patricia B ^a   Burmeister, Melissa A ^b   Tomlinson, Stephen ^c   D'Agati, Vivette D ^d   Davisson, Robin L ^b,e   Salmon, Jane E ^a,e  

^a HOSPITAL FOR SPECIAL SURGERY   (United States)

^b Department of Obstetrics Gynecology   (United States)

^c MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^d College of Physicians and Surgeons ^*  (United States)

^e WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

complement; placenta; preeclampsia; pregnancy

Indexed keywords

COMPLEMENT INHIBITOR; CR2 CRRY FUSION PROTEIN; FIBRIN; NITROGEN; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; UREA; VASCULOTROPIN 121;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPLEMENT ACTIVATION; COMPLEMENT INHIBITION; CONTROLLED STUDY; DRUG BINDING SITE; DRUG EFFECT; DRUG EFFICACY; DRUG TARGETING; FEMALE; FIBRIN DEPOSITION; GLOMERULAR ENDOTHELIOSIS; HISTOPATHOLOGY; KIDNEY DISEASE; MALE; MATING; MOUSE; MOUSE STRAIN; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLACENTA DISORDER; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; PROTEINURIA; SINGLE DRUG DOSE; UREA NITROGEN BLOOD LEVEL;

EID: 78651381284     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2010.393     Document Type: Article

References (60)

1. Ilekis JV, Reddy UM, Roberts JM. Preeclampsia-a pressing problem: an executive summary of a National Institute of Child Health and Human Development workshop. Reprod Sci 2007; 14: 508-523.
2. Roberts JM, Gammill HS. Preeclampsia: recent insights. Hypertension 2005; 46: 1243-1249.
3. Gilbert JS, Babcock SA, Granger JP. Hypertension produced by reduced uterine perfusion in pregnant rats is associated with increased soluble fms-like tyrosine kinase-1 expression. Hypertension 2007; 50: 1142-1147.
4. Makris A, Thornton C, Thompson J et al. Uteroplacental ischemia results in proteinuric hypertension and elevated sFLT-1. Kidney Int 2007; 71: 977-984.
5. Nevo O, Soleymanlou N, Wu Y et al. Increased expression of sFlt-1 in in vivo and in vitro models of human placental hypoxia is mediated by HIF-1. Am J Physiol Regul Integr Comp Physiol 2006; 291: R1085-R1093.
6. Young BC, Levine RJ, Karumanchi SA. Pathogenesis of preeclampsia. Annu Rev Pathol 2010; 5: 173-192.
7. Maynard SE, Min JY, Merchan J et al. Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J Clin Invest 2003; 111: 649-658.
8. Levine RJ, Maynard SE, Qian C et al. Circulating angiogenic factors and the risk of preeclampsia. N Engl J Med 2004; 350: 672-683.
9. Zhu X, Wu S, Dahut WL et al. Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis. Am J Kidney Dis 2007; 49: 186-193.
10. Girardi G, Yarilin D, Thurman JM et al. Complement activation induces dysregulation of angiogenic factors and causes fetal rejection and growth restriction. J Exp Med 2006; 203: 2165-2175.
11. Lynch AM, Gibbs RS, Murphy JR et al. Complement activation fragment Bb in early pregnancy and spontaneous preterm birth. Am J Obstet Gynecol 2008; 199: 354 e351-358.
12. Girardi G, Bulla R, Salmon JE et al. The complement system in the pathophysiology of pregnancy. Mol Immunol 2006; 43: 68-77.
13. Salmon JE, Girardi G. Antiphospholipid antibodies and pregnancy loss: a disorder of inflammation. J Reprod Immunol 2008; 77: 51-56.
14. Rampersad R, Barton A, Sadovsky Y et al. The C5b-9 membrane attack complex of complement activation localizes to villous trophoblast injury in vivo and modulates human trophoblast function in vitro. Placenta 2008; 29: 855-861.
15. Fang CJ, Richards A, Liszewski MK et al. Advances in understanding of pathogenesis of aHUS and HELLP. Br J Haematol 2008; 143: 336-348.
16. Fakhouri F, Roumenina L, Provot F et al. Pregnancy-associated hemolytic uremic syndrome revisited in the era of complement gene mutations. J Am Soc Nephrol 2010; 21: 859-867.
17. Song H, He C, Knaak C et al. Complement receptor 2-mediated targeting of complement inhibitors to sites of complement activation. J Clin Invest 2003; 111: 1875-1885.
18. Atkinson C, Song H, Lu B et al. Targeted complement inhibition by C3d recognition ameliorates tissue injury without apparent increase in susceptibility to infection. J Clin Invest 2005; 115: 2444-2453.
19. Atkinson C, Qiao F, Song H et al. Low-dose targeted complement inhibition protects against renal disease and other manifestations of autoimmune disease in MRL/lpr mice. J Immunol 2008; 180: 1231-1238.
20. Banda NK, Levitt B, Glogowska MJ et al. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol 2009; 183: 5928-5937.
21. Clark DA, Chaouat G, Arck PC et al. Cytokine-dependent abortion in CBA x DBA/2 mice is mediated by the procoagulant fgl2 prothrombinase [correction of prothombinase]. J Immunol 1998; 160: 545-549.
22. Fareed J, Hoppensteadt DA, Leya F et al. Useful laboratory tests for studying thrombogenesis in acute cardiac syndromes. Clin Chem 1998; 44: 1845-1853.
23. Redecha P, van Rooijen N, Torry D et al. Pravastatin prevents miscarriages in mice: role of tissue factor in placental and fetal injury. Blood 2009; 113: 4101-4109.
24. Sheehan HL. Renal morphology in preeclampsia. Kidney Int 1980; 18: 241-252.
25. Gaber LW, Spargo BH, Lindheimer MD. Renal pathology in pre-eclampsia. Baillieres Clin Obstet Gynaecol 1994; 8: 443-468.
26. Kincaid-Smith P. The renal lesion of preeclampsia revisited. Am J Kidney Dis 1991; 17: 144-148.
27. Croy BA, He H, Esadeg S et al. Uterine natural killer cells: insights into their cellular and molecular biology from mouse modelling. Reproduction 2003; 126: 149-160.
28. Caron K, Hagaman J, Nishikimi T et al. Adrenomedullin gene expression differences in mice do not affect blood pressure but modulate hypertension-induced pathology in males. Proc Natl Acad Sci USA 2007; 104: 3420-3425.
29. Douglas KA, Redman CW. Eclampsia in the United Kingdom. Bmj 1994; 309: 1395-1400.
30. Atkinson C, Zhu H, Qiao F et al. Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol 2006; 177: 7266-7274.
31. Molina H, Wong W, Kinoshita T et al. Distinct receptor and regulatory properties of recombinant mouse complement receptor 1 (CR1) and Crry, the two genetic homologues of human CR1. J Exp Med 1992; 175: 121-129.
32. Walsh SW, Vaughan JE, Wang Y et al. Placental isoprostane is significantly increased in preeclampsia. Faseb J 2000; 14: 1289-1296.
33. Roberts JM, Lain KY. Recent Insights into the pathogenesis of preeclampsia. Placenta 2002; 23: 359-372.
34. Fisher SJ. The placental problem: linking abnormal cytotrophoblast differentiation to the maternal symptoms of preeclampsia. Reprod Biol Endocrinol 2004; 2: 53.
35. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 2005; 308: 1592-1594.
36. Maynard S, Epstein FH, Karumanchi SA. Preeclampsia and angiogenic imbalance. Annu Rev Med 2008; 59: 61-78.
37. Girardi G, Berman J, Redecha P et al. Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome. J Clin Invest 2003; 112:1644-1654.
38. Levine RJ, Lam C, Qian C et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006; 355: 992-1005.
39. Li Z, Zhang Y, Ying Ma J et al. Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia. Hypertension 2007; 50: 686-692.
40. Gilbert JS, Verzwyvelt J, Colson D et al. Recombinant vascular endothelial growth factor 121 infusion lowers blood pressure and improves renal function in rats with placentalischemia-induced hypertension. Hypertension 2010; 55: 380-385.
41. Chaouat G, Clark DA, Wegmann TG. Genetic aspects of the CBA x DBA/2 and B10 x B10. A model of murine abortion and its prevention by lymphocytes immunization. In: Allen WR, Clark DA, Gill TJ, Mowbray JF, Robertson WE (eds). Early Pregnancy Loss: Mechanisms and Treatment. RCOG Press: London, 1988: 89-102.
42. Zenclussen AC, Gerlof K, Zenclussen ML et al. Abnormal T-cell reactivity against paternal antigens in spontaneous abortion: adoptive transfer of pregnancy-induced CD4+CD25+ T regulatory cells prevents fetal rejection in a murine abortion model. Am J Pathol 2005; 166: 811-822.
43. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 2005; 365: 785-799.
44. Li M, Yee D, Magnuson TR et al. Reduced maternal expression of adrenomedullin disrupts fertility, placentation, and fetal growth in mice. J Clin Invest 2006; 116: 2653-2662.
45. Kanasaki K, Palmsten K, Sugimoto H et al. Deficiency in catechol-O-methyltransferase and 2-methoxyoestradiol is associated with preeclampsia. Nature 2008; 453: 1117-1121.
46. Cudmore M, Ahmad S, Al-Ani B et al. Negative regulation of soluble Flt-1 and soluble endoglin release by heme oxygenase-1. Circulation 2007; 115: 1789-1797.
47. Zhou CC, Zhang Y, Irani RA et al. Angiotensin receptor agonistic autoantibodies induce pre-eclampsia in pregnant mice. Nat Med 2008; 14: 855-862.
48. Xu C, Mao D, Holers VM et al. A critical role for murine complement regulator crry in fetomaternal tolerance. Science 2000; 287: 498-501.
49. Holers VM, Girardi G, Mo L et al. Complement C3 activation is required for antiphospholipid antibody-induced fetal loss. J Exp Med 2002; 195: 211-220. (Pubitemid 34461265)
50. Mellor AL, Sivakumar J, Chandler P et al. Prevention of T cell-driven complement activation and inflammation by tryptophan catabolism during pregnancy. Nat Immunol 2001; 2: 64-68.
51. Guleria I, Khosroshahi A, Ansari MJ et al. A critical role for the programmed death ligand 1 in fetomaternal tolerance. J Exp Med 2005; 202: 231-237.
52. Thurman JM, Renner B, Kunchithapautham K et al. Oxidative stress renders retinal pigment epithelial cells susceptible to complement-mediated injury. J Biol Chem 2009; 284: 16939-16947.
53. Eremina V, Jefferson JA, Kowalewska J et al. VEGF inhibition and renal thrombotic microangiopathy. N Engl J Med 2008; 358: 1129-1136.
54. Holston AM, Qian C, Yu KF et al. Circulating angiogenic factors in gestational proteinuria without hypertension. Am J Obstet Gynecol 2009; 200: 392 e391-310.
55. Haeger M, Unander M, Norder-Hansson B et al. Complement, neutrophil, and macrophage activation in women with severe preeclampsia and the syndrome of hemolysis, elevated liver enzymes, and low platelet count. Obstet Gynecol 1992; 79: 19-26.
56. Rey E, Garneau P, David M et al. Dalteparin for the prevention of recurrence of placental-mediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost 2009; 7: 58-64.
57. Girardi G, Redecha P, Salmon JE. Heparin prevents antiphospholipid antibody-induced fetal loss by inhibiting complement activation. Nat Med 2004; 10: 1222-1226.
58. Seshan SV, Franzke CW, Redecha P et al. Role of tissue factor in a mouse model of thrombotic microangiopathy induced by antiphospholipid (aPL) antibodies. Blood 2009; 114: 1675-1683.
59. Davisson RL, Hoffmann DS, Butz GM et al. Discovery of a spontaneous genetic mouse model of preeclampsia. Hypertension 2002; 39: 337-342.
60. Hoffmann DS, Weydert CJ, Lazartigues E et al. Chronic tempol prevents hypertension, proteinuria, and poor feto-placental outcomes in BPH/5 mouse model of preeclampsia. Hypertension 2008; 51: 1058-1065.